Drug Trial Radar · NCT05304936
HCW9218 for Advanced Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
Oct 17, 2022
Primary completion
Feb 15, 2025
Study completion Feb 15, 2025
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.
Conditions
- Advanced Pancreatic Carcinoma
Interventions
HCW9218Drug
Bifunctional TGF-β (Transforming Growth Factor Beta) antagonist/IL-15 (Interleukin-15) protein complex
Gemcitabine (GEM)Drug
Gemcitabine is administered as a combination chemotherapy regimen for the treatment of advanced/metastatic pancreatic cancer in accordance with standard-of-care dosing and schedule per protocol
Nab-paclitaxelDrug
Nab-paclitaxel is administered as a combination chemotherapy regimen for the treatment of advanced/metastatic pancreatic cancer in accordance with standard-of-care dosing and schedule per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Adverse Events and Treatment-Related Adverse EventsTime frame: 12 Months
- Determine the maximum tolerated dose (MTD)Time frame: 12 Months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona
National Institute of Health/ National Cancer Institute
Bethesda, Maryland
Washington University in St. Louis
St Louis, Missouri
Cleveland Clinic
Cleveland, Ohio
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.